<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>tumor-immune microenvironment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tumor-immune-microenvironment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 20 Jan 2026 16:04:57 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>tumor-immune microenvironment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Neutrophil Extracellular Traps: Hidden Players in Cancer</title>
		<link>https://bioengineer.org/neutrophil-extracellular-traps-hidden-players-in-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 16:04:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer metastasis]]></category>
		<category><![CDATA[Cancer Therapy Resistance** **Açıklama:** 1. **NETosis:** Makalenin temel konusu olan nötrofillerin bu spesifik ölüm ve tuzak oluşturma sürecini doğrudan hedef alır. 2.]]></category>
		<category><![CDATA[İçeriğe göre en uygun 5 etiket: **NETosis in cancer]]></category>
		<category><![CDATA[Immunosuppression in Cancer]]></category>
		<category><![CDATA[Immunosuppression in cancer** * **NETosis in cancer:** Makalenin ana konusu ve NET'lerin oluşum mekanizması vurgulanıyor. * **Tumor microenvironment (TIME):** NET'lerin etkilerinin gösterildiği ba]]></category>
		<category><![CDATA[İşte içerikle tam uyumlu 5 etiket: **NETosis]]></category>
		<category><![CDATA[Neutrophil extracellular traps]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neutrophil-extracellular-traps-hidden-players-in-cancer/</guid>

					<description><![CDATA[Recent research has shed light on the complex interactions within the tumor immune microenvironment (TIME), particularly the role of neutrophils in cancer progression. Neutrophils, which are essential components of the innate immune system, have been observed to engage in a process known as NETosis. This process results in the release of neutrophil extracellular traps (NETs), [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319020</post-id>	</item>
		<item>
		<title>N6-Methyladenosine: Key RNA Modifier in Cancer Regulation</title>
		<link>https://bioengineer.org/n6-methyladenosine-key-rna-modifier-in-cancer-regulation/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 20:02:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[and implications of N6-methyladenosine (m6A) in cancer biology and therapy]]></category>
		<category><![CDATA[Based on the content focusing on the role]]></category>
		<category><![CDATA[Cancer epigenetics** **Explanation:** 1. **m6A in cancer:** Directly states the core subject of the article. 2. **RNA methylation regulation:** Describes the broader process central]]></category>
		<category><![CDATA[here are 5 appropriate tags: **m6A in cancer]]></category>
		<category><![CDATA[m6A writers erasers readers]]></category>
		<category><![CDATA[m6A-targeted cancer therapies]]></category>
		<category><![CDATA[mechanisms]]></category>
		<category><![CDATA[METTL3 in cancer regulation]]></category>
		<category><![CDATA[METTL3 inhibitors]]></category>
		<category><![CDATA[N6-Methyladenosine RNA modification]]></category>
		<category><![CDATA[RNA methylation and immune evasion]]></category>
		<category><![CDATA[RNA methylation regulation]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/n6-methyladenosine-key-rna-modifier-in-cancer-regulation/</guid>

					<description><![CDATA[In the intricate landscape of molecular oncology, the role of RNA modifications has emerged as a compelling area of investigation. Among these post-transcriptional modifications, N^6-methyladenosine (m^6A) stands out as a critical player, heavily influencing gene expression and cellular function. This modification is not merely a marker of regulatory complexity but a vital determinant in the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318538</post-id>	</item>
		<item>
		<title>PLXNA3 Gene: Impact on Breast Cancer Prognosis</title>
		<link>https://bioengineer.org/plxna3-gene-impact-on-breast-cancer-prognosis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 07 Jan 2026 23:07:08 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[İçeriğin odak noktalarına (PLXNA3 geni]]></category>
		<category><![CDATA[immün özellikler]]></category>
		<category><![CDATA[Immune cell infiltration]]></category>
		<category><![CDATA[meme kanseri prognozu]]></category>
		<category><![CDATA[moleküler mekanizma) göre uygun 5 etiket: **PLXNA3 breast cancer]]></category>
		<category><![CDATA[prognostic biomarker]]></category>
		<category><![CDATA[Semaphorin signaling** * **PLXNA3 breast cancer:** Ana konu olan gen ve kanser t]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/plxna3-gene-impact-on-breast-cancer-prognosis/</guid>

					<description><![CDATA[The world of cancer research is continuously evolving, with scientists constantly searching for new biomarkers and genetic indicators that can influence prognosis and treatment response. A recent study has emerged from this ongoing quest, shedding light on the PLXNA3 gene in relation to breast cancer. This fundamental research provides a comprehensive analysis that holds the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">314634</post-id>	</item>
		<item>
		<title>DPPC Drives Colorectal Cancer Progression and Immune Change</title>
		<link>https://bioengineer.org/dppc-drives-colorectal-cancer-progression-and-immune-change/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 04 Jan 2026 09:13:36 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[DPPC and colorectal cancer progression]]></category>
		<category><![CDATA[lipid metabolism in cancer]]></category>
		<category><![CDATA[Machine learning in cancer research]]></category>
		<category><![CDATA[multi-omics technologies]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/dppc-drives-colorectal-cancer-progression-and-immune-change/</guid>

					<description><![CDATA[In a groundbreaking study, researchers have unveiled the intricate relationship between dipalmitoylphosphatidylcholine (DPPC) and colorectal cancer (CRC) progression. This research, leveraging multi-omics technologies and advanced machine learning methodologies, provides compelling evidence that DPPC plays a pivotal role in the dynamics of tumor development and the remodeling of its immune microenvironment. The study, appearing in the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">313513</post-id>	</item>
		<item>
		<title>Extracellular Vesicles: Tumor Immune Microenvironment Influence</title>
		<link>https://bioengineer.org/extracellular-vesicles-tumor-immune-microenvironment-influence/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 13 Dec 2025 10:07:57 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cancer therapy]]></category>
		<category><![CDATA[EV biogenesis]]></category>
		<category><![CDATA[extracellular vesicles]]></category>
		<category><![CDATA[immunomodulation]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/extracellular-vesicles-tumor-immune-microenvironment-influence/</guid>

					<description><![CDATA[Extracellular vesicles (EVs) are increasingly recognized as pivotal players in intercellular communication, particularly concerning their significant impacts on the tumor immune microenvironment. The recent research highlighted by Yeat and Chen delves into the biogenesis mechanisms of these vesicles and elucidates their roles in modulating immune responses within tumors. The intricate nature of EVs and their [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">307220</post-id>	</item>
		<item>
		<title>Prognostic Model for Colorectal Cancer Developed</title>
		<link>https://bioengineer.org/prognostic-model-for-colorectal-cancer-developed/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 01 Oct 2025 13:38:07 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[colorectal cancer prognostic biomarkers]]></category>
		<category><![CDATA[gene co-expression network analysis]]></category>
		<category><![CDATA[microsatellite stability-associated genes]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/prognostic-model-for-colorectal-cancer-developed/</guid>

					<description><![CDATA[In a groundbreaking advance in colorectal cancer (CRC) research, scientists have unveiled a novel prognostic risk model grounded in genes associated with microsatellite stability (MSS). This innovative approach targets a pressing challenge in CRC treatment: the high recurrence rate that significantly undermines patient survival. By focusing on molecular differences linked to microsatellite instability (MSI), a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">274374</post-id>	</item>
		<item>
		<title>Gene Panel Predicts Response to Crucial Breast Cancer Therapy</title>
		<link>https://bioengineer.org/gene-panel-predicts-response-to-crucial-breast-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 25 Sep 2025 14:55:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[breast cancer genomic biomarkers]]></category>
		<category><![CDATA[CDK4/6 inhibitor response prediction]]></category>
		<category><![CDATA[HR+/HER2- breast cancer]]></category>
		<category><![CDATA[KIMA transcriptomic signature]]></category>
		<category><![CDATA[personalized breast cancer therapy]]></category>
		<category><![CDATA[personalized cancer treatment]]></category>
		<category><![CDATA[predictive biomarkers in oncology]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/gene-panel-predicts-response-to-crucial-breast-cancer-therapy/</guid>

					<description><![CDATA[Researchers unveil a groundbreaking immune-based genomic signature that promises to revolutionize treatment strategies for hormone receptor-positive, HER2-negative breast cancer by predicting patient responses to CDK4/6 inhibitors, a cornerstone therapy for this cancer subtype. This advancement, emerging from a collaborative study led by IrsiCaixa, the Catalan Institute of Oncology (ICO), and the Germans Trias i Pujol [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">272232</post-id>	</item>
		<item>
		<title>CDC6: Pan-Cancer Biomarker Suppressing Melanoma</title>
		<link>https://bioengineer.org/cdc6-pan-cancer-biomarker-suppressing-melanoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 24 Sep 2025 19:55:39 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CDC6 biomarker]]></category>
		<category><![CDATA[melanoma suppression mechanisms]]></category>
		<category><![CDATA[multi-omics cancer research]]></category>
		<category><![CDATA[oncogenic therapeutic targets]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cdc6-pan-cancer-biomarker-suppressing-melanoma/</guid>

					<description><![CDATA[In the ever-evolving landscape of cancer research, cell cycle regulators have emerged as pivotal players in tumor biology. A recent breakthrough study published in BMC Cancer introduces CDC6 (Cell Division Cycle 6) as a significant oncogenic driver with broad implications across multiple cancer types. This study transcends traditional boundaries, revealing CDC6’s multi-faceted roles not only [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">271902</post-id>	</item>
		<item>
		<title>E3 Ligases, Deubiquitinases Control PD-L1 in RCC</title>
		<link>https://bioengineer.org/e3-ligases-deubiquitinases-control-pd-l1-in-rcc/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 06 Aug 2025 04:32:27 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[E3 ligases-deubiquitinases axis]]></category>
		<category><![CDATA[PD-L1 regulation]]></category>
		<category><![CDATA[Renal cell carcinoma]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<category><![CDATA[Ubiquitination in cancer immunotherapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/e3-ligases-deubiquitinases-control-pd-l1-in-rcc/</guid>

					<description><![CDATA[In the relentless search to understand cancer’s evasive tactics, renal cell carcinoma (RCC), a complex kidney malignancy, stands out for its enigmatic interplay with the immune system. Central to this interaction is the programmed death-ligand 1 (PD-L1), a protein that tumors deploy to suppress immune attacks, effectively cloaking themselves from the body’s natural defenses. Recent [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">253714</post-id>	</item>
		<item>
		<title>RBM17 Drives Liver Cancer via Lipid, Immunity Changes</title>
		<link>https://bioengineer.org/rbm17-drives-liver-cancer-via-lipid-immunity-changes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 02 Aug 2025 01:19:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[lipid metabolism reprogramming]]></category>
		<category><![CDATA[RBM17]]></category>
		<category><![CDATA[Targeted cancer therapies]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/rbm17-drives-liver-cancer-via-lipid-immunity-changes/</guid>

					<description><![CDATA[In a groundbreaking new study published in Cell Death Discovery, researchers have uncovered critical insights into the molecular mechanisms driving hepatocellular carcinoma (HCC), the most common form of liver cancer globally. The team, led by Wang, Liu, and Lai, has identified the RNA-binding motif protein 17 (RBM17) as a central regulator in the progression of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">252567</post-id>	</item>
		<item>
		<title>Unraveling MMP1+ Tumor Cells’ Immune Impact</title>
		<link>https://bioengineer.org/unraveling-mmp1-tumor-cells-immune-impact/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 May 2025 20:09:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Cancer immune evasion]]></category>
		<category><![CDATA[matrix metalloproteinases in cancer]]></category>
		<category><![CDATA[MMP1+ tumor cells]]></category>
		<category><![CDATA[single-cell and spatial transcriptomics]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/unraveling-mmp1-tumor-cells-immune-impact/</guid>

					<description><![CDATA[In a groundbreaking study published in Cell Death Discovery, researchers have unveiled pivotal insights into the complex interplay between malignant tumor cells and the immune microenvironment, shedding new light on cancer progression and therapeutic resistance. By employing cutting-edge single-cell and spatial transcriptomic technologies, the team led by Xu, Chen, Xue, and colleagues has meticulously decoded [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">246003</post-id>	</item>
	</channel>
</rss>
